Sponsor: Immunomedics, Inc.
Sponsor Study ID: IMMU-132-06
Study Title: A Phase II Open Label, Study of IMMU 132 in Metastatic Urothelial Cancer After Failure of Platinum Based Regimen or Anti PD 1/PD L1 Based Immunotherapy
CTO #: 103491
NCT Number: NCT03547973
Phase: II
Protocol Type: Treatment
Age Group: Adults
Disease Sites: Bladder
Study Objectives: The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy in participants with metastatic urothelial cancer (mUC).